Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saar Gill

Showing results (71-80 of 92) with videos related to

Pageof 10
Sort By:
Cell|September 4, 2010
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphomaMark P Chao, Ash A Alizadeh, Chad Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2019
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic LeukemiaNoelle V Frey, Pamela A Shaw, Elizabeth O Hexner, et al.
Blood Advances|January 31, 2025
Evolving racial/ethnic disparities in AML survival in the novel therapy eraXin Wang, Phyllis A Gimotty, Andrew H Matthews, et al.
The Journal of Clinical Investigation|August 30, 2016
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapiesMarco Ruella, David M Barrett, Saad S Kenderian, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 26, 2021
Prediction and validation of hematopoietic stem and progenitor cell off-target editing in transplanted rhesus macaquesAisha A AlJanahi, Cicera R Lazzarotto, Shirley Chen, et al.
Cancer Discovery|February 1, 2020
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell DysfunctionNathan Singh, Yong Gu Lee, Olga Shestova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2022
Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19Caroline Diorio, Rawan Shraim, Regina Myers, et al.
Cell|June 2, 2018
Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid LeukemiaMiriam Y Kim, Kyung-Rok Yu, Saad S Kenderian, et al.
Nature Communications|March 20, 2025
Author Correction: Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical modelsStefano Pierini, Rashid Gabbasov, Maria Cecilia Oliveira-Nunes, et al.
Nature Medicine|February 7, 2025
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trialKim A Reiss, Mathew G Angelos, E Claire Dees, et al.
Pageof 10

Showing results (71-80 of 92) with videos related to

Sort By:
Pageof 10
Cell|September 4, 2010
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphomaMark P Chao, Ash A Alizadeh, Chad Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2019
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic LeukemiaNoelle V Frey, Pamela A Shaw, Elizabeth O Hexner, et al.
Blood Advances|January 31, 2025
Evolving racial/ethnic disparities in AML survival in the novel therapy eraXin Wang, Phyllis A Gimotty, Andrew H Matthews, et al.
The Journal of Clinical Investigation|August 30, 2016
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapiesMarco Ruella, David M Barrett, Saad S Kenderian, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 26, 2021
Prediction and validation of hematopoietic stem and progenitor cell off-target editing in transplanted rhesus macaquesAisha A AlJanahi, Cicera R Lazzarotto, Shirley Chen, et al.
Cancer Discovery|February 1, 2020
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell DysfunctionNathan Singh, Yong Gu Lee, Olga Shestova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2022
Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19Caroline Diorio, Rawan Shraim, Regina Myers, et al.
Cell|June 2, 2018
Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid LeukemiaMiriam Y Kim, Kyung-Rok Yu, Saad S Kenderian, et al.
Nature Communications|March 20, 2025
Author Correction: Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical modelsStefano Pierini, Rashid Gabbasov, Maria Cecilia Oliveira-Nunes, et al.
Nature Medicine|February 7, 2025
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trialKim A Reiss, Mathew G Angelos, E Claire Dees, et al.
Pageof 10